[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-cancer-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-cancer-recurrent":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,88,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100644293","phase-1-a-phase-1-study-to-evaluate-the-safety-and-efficacy-of-opb-201-in-recurrent-endometrial-and-platinum-resistant-ovarian-cancer-100644293",false,"NCT07664735","A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.","A Phase 1a\u002Fb Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.","Inclusion Criteria:\n\n1. Age ≥ 18 years of age at the time of signing the informed consent form.\n2. Histologically confirmed diagnosis of endometrial cancer, epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.\n3. Received at least 1 prior line of systemic chemotherapy including a platinum-based chemotherapy.\n4. Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1\u002F2 mutation.\n5. Measurable disease.\n6. Consent to provide archived tumor tissue sample.\n7. ECOG performance status of 0 or 1.\n8. Adequate organ function.\n9. HLA-A \\*02:01 or HLA-A \\*02:02\n10. PRAME positive tumor\n\nExclusion Criteria:\n\n1. Women of child-bearing potential who are pregnant or breastfeeding.\n2. Uncontrolled bacterial, fungal, or viral infections.\n3. Active infection requiring systemic therapy.\n4. Bleeding or thrombotic disorders or at risk for severe hemorrhage.\n5. Any form of primary immunodeficiency.\n6. Had an allogenic tissue\u002Fsolid organ transplant.\n7. Active autoimmune disease.\n8. Concurrent treatment with systemic high dose corticosteroids.\n9. Unresolved acute effects of any prior therapy.\n10. Other exclusions as stated in the protocol.","FEMALE","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.",[26,27,28,29,30,31,32],"Endometrial Cancer Recurrent","Endometrial Cancer","Advanced Endometrial Cancer","Ovarian Cancer","Ovarian Cancer Recurrent","Platinum Resistant Ovarian Cancer","Endometrial Cancers",[34,35,36,37,38,39,40,41,42],"Outpace","Ovarian cancer","Endometrial cancer","advanced ovarian cancer","advanced endometrial cancer","cell therapy","TCR-T","TCR","PRAME directed TCR","NOT_YET_RECRUITING","2026-06-17",{"date":46,"type":47},"2026-06-24","ACTUAL",{"date":49,"type":20},"2026-06-30",{"date":51,"type":20},"2030-09",{"name":53,"class":54},"Outpace Bio, Inc.","INDUSTRY",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":63,"targetDuration":65,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100576119","a-study-to-explore-personalized-treatment-for-patients-with-recurrent-gynecological-malignancies-based-on-mtb-100576119","NCT06781151","A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB","A Real-world Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on Molecular Profiling and Multidisciplinary Team Consultation","RWS-MTB","Inclusion Criteria:\n\n* Patients with recurrent ovarian, cervical, or endometrial cancer referred for multidisciplinary consultation by a gynecological oncologist;\n* Presence of at least one evaluable lesion;\n* Willingness to participate in multidisciplinary consultation;\n* Age 18 years or older;\n* Sufficient tumor tissue for next-generation sequencing (NGS) with a tumor content greater than 32%;\n* Informed consent provided by the participant, indicating understanding of the study procedures and willingness to participate.\n\nExclusion Criteria:\n\n* Patients with concurrent malignancies;\n* Pregnant patients.",{"count":64,"type":20},200,"2 Years","OBSERVATIONAL","This is a non-interventional, real-world study divided into two parts: a retrospective study and a prospective study.\n\nThe main question it aims to answer is:\n\nWill genomic sequencing and molecular tumor boards lead to clinical responses in patients with recurrent ovarian, cervical, or endometrial cancer? The retrospective arm will analyze data from patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) who underwent multidisciplinary consultations at our institution from January 2022 onward. Data collected will include tumor tissue genomic sequencing results, medical histories, multidisciplinary consultation recommendations, and subsequent treatment courses. This analysis will examine the implementation and clinical efficacy of personalized targeted therapies guided by molecular tumor profiling and multidisciplinary consultation.\n\nThe prospective arm will enroll 200 patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) referred for multidisciplinary consultation. Tumor tissue and blood samples will undergo next-generation sequencing (NGS) to determine molecular tumor profiles. A multidisciplinary expert panel will formulate individualized treatment strategies based on these profiles, patient clinical data, and treatment history. Attending physicians will determine the final treatment plan, integrating multidisciplinary recommendations with patient preferences, comorbidity considerations, drug toxicity assessments, insurance coverage for off-label medications, and the availability of investigational drug trials. This arm aims to observe and evaluate the clinical efficacy of personalized treatment plans developed through molecular tumor profiling and multidisciplinary consultation.",[30,26,69],"Cervical Cancer Recurrent",[71,72,73,74,75],"genomic sequencing","molecular tumor boards","recurrent ovarian cancer","recurrent endometrial cancer","recurrent cervical cancer","RECRUITING","2025-08-20",{"date":79,"type":47},"2025-08-27",{"date":81,"type":47},"2024-04-24",{"date":83,"type":20},"2027-06-18",{"name":85,"class":86},"Sun Yat-sen University","OTHER",2,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":95,"minAge":17,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100470811","phase-1-cldn6gpc3mesothelinaxl-car-nk-cell-therapy-for-advanced-solid-tumors-100470811","NCT05410717","CLDN6\u002FGPC3\u002FMesothelin\u002FAXL-CAR-NK Cell Therapy for Advanced Solid Tumors","Phase I Trial to Evaluate Safety and Preliminary Efficacy of CLDN6\u002FGPC3\u002FMesothelin\u002FAXL-CAR-NK in Patients With CLDN6\u002FGPC3\u002FMesothelin\u002FAXL-positive Advanced Solid Tumors","Inclusion Criteria:\n\n1. patients with advanced ovarian cancer or other cancers with expression of claudin6.\n2. Life expectancy \\>12 weeks\n3. Adequate heart,lung,liver,kidney function\n4. Available autologous transduced NK cells with greater than or equal to 20% expression of Claudin6, GPC3, Mesothelin, or AXL-CAR determined by flow-cytometry and killing of claudin6-positive targets greater than or equal to 20% in cytotoxicity assay\n5. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent. -\n\nExclusion Criteria:\n\n1. Had accepted gene therapy before;\n2. Tumor size more than 25cm;\n3. Severe virus infection such as HBV,HCV,HIV,et al\n4. Known HIV positivity\n5. History of liver\u002Frenal transplantation\n6. Active infectious disease related to bacteria, virus,fungi,et al\n7. Other severe diseases that the investigators consider not appropriate;\n8. Pregnant or lactating women\n9. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent\u002Fkg\u002Fday)\n10. Other conditions that the investigators consider not appropriate. -","ALL","75 Years",{"count":64,"type":20},[23],"This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others)",[101,102,26,103],"Stage IV Ovarian Cancer","Testis Cancer, Refractory","CAR NK",[105,106,103,107,108,109,110,111,112,113,114,115,116],"Solid tumor","Claudin6","GPC3","Mesothelin","AXL","Cannabidiol","Nicotinamide adenine dinucleotide","IL7","CCL19","PD1 antibody","PDL1 antibody","CTLA1 antibody","2024-06-22",{"date":119,"type":47},"2024-06-25",{"date":121,"type":47},"2022-06-01",{"date":123,"type":20},"2036-05-31",{"name":125,"class":86},"Second Affiliated Hospital of Guangzhou Medical University",1,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":65,"studyType":66,"phases":4,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":126},"100333482","promote-study-prediction-of-response-of-hormonal-treatment-in-advanced-and-recurrent-endometrial-cancer-100333482","NCT03621904","PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer","PROMOTE","Inclusion Criteria:\n\n* Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer\n* All histologic types of endometrial carcinoma\n* Planned treatment with any type of hormonal therapy\n* Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy.\n\nExclusion Criteria:\n\n* Adjuvant hormonal therapy started following complete resection of endometrial carcinoma\n* Synchronous use of hormonal therapy for other indications\n* Endometrial sarcoma or endometrial stroma cell sarcoma","110 Years",{"count":136,"type":20},150,"The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy",[139,140,26],"Endometrial Cancer Stage III","Endometrial Cancer Stage IV",[142,143,144,145],"Hormonal therapy","Endocrine therapy","Translational research","Tumor factors","2023-01-17",{"date":148,"type":47},"2023-01-18",{"date":150,"type":47},"2022-10-15",{"date":152,"type":20},"2027-09-01",{"name":154,"class":86},"Radboud University Medical Center"]